IL 1RA Porcine
(a) Analysis by RP-HPLC.
(b) Analysis by SDS-PAGE.
THE BioTek's products are furnished for LABORATORY RESEARCH USE ONLY. The product may not be used as drugs, agricultural or pesticidal products, food additives or household chemicals.
Description
Product Specs
The ED50, determined by the inhibition of IL-1α-dependent proliferation in murine D10S cells, is less than 50 ng/ml. This corresponds to a specific activity exceeding 2.0 × 104 IU/mg in the presence of 75 pg/ml of recombinant Porcine IL-1α.
Product Science Overview
Interleukin-1 Receptor Antagonist (IL-1Ra) is a naturally occurring anti-inflammatory protein that plays a crucial role in regulating the immune response. It is part of the interleukin-1 family of cytokines, which are involved in various inflammatory processes. The recombinant form of IL-1Ra, derived from porcine sources, has been developed to study its effects and potential therapeutic applications.
IL-1Ra was first discovered in 1984 in the urine and serum of patients with leukemia and in the supernatant of cultured monocytes . It was named for its ability to competitively bind to the interleukin-1 receptor, thereby antagonizing the function of interleukin-1 (IL-1). This discovery opened up new avenues for research into the regulation of inflammatory responses and the development of anti-inflammatory therapies.
IL-1Ra works by binding to the interleukin-1 receptor without activating it, effectively blocking the binding of pro-inflammatory cytokines such as IL-1α and IL-1β . This inhibition helps to reduce inflammation and protect against immune dysregulation and uncontrolled systemic inflammation triggered by various stimulatory agents, including pathogens .
The recombinant form of IL-1Ra derived from porcine sources has been developed to explore its potential in veterinary medicine and research. Porcine IL-1Ra has been studied for its immunomodulatory effects, particularly in the context of porcine reproductive and respiratory syndrome virus (PRRSV) infection . Research has shown that PRRSV-induced IL-1Ra can impair innate and adaptive immune responses, highlighting its role in viral immunosuppression .
Recombinant IL-1Ra, such as anakinra, has been used in the treatment of autoimmune diseases like rheumatoid arthritis . Anakinra is a slightly modified version of IL-1Ra that has shown efficacy in reducing the signs and symptoms of rheumatoid arthritis when used in combination with methotrexate . The success of anakinra in human medicine has spurred interest in exploring the therapeutic potential of recombinant IL-1Ra in veterinary applications.
